Navigation Links
Clemson University and the University of Queensland form biofuels research partnership
Date:6/27/2011

earch, and this collaboration will aid process development and help speed these processes to market.

"The University of Queensland is one of Australia's premier learning and research institutions," Kelly said. "Together, we will push the boundaries of biofuels development with alternative energy concepts that benefit South Carolina and Queensland."

The research scope includes:

  • Switchgrass and sweet sorghum to ethanol: Clemson will provide comprehensive access to information developed for conversion of sugar cane bagasse (the fibrous byproduct of sugar extraction) to ethanol.
  • Ethanol pilot-scale demonstration funding: Clemson and Queensland will develop and pilot a sugar cane-to-ethanol process in Queensland using residual sugar cane bagasse.
  • Cellulosic monomer conversion to biodiesel technology: The universities will develop algal and cellulosic technologies for the production of biodiesel. This process, in early developmental phases, has the potential to convert cellulose from multiple feedstock sources to a ready biodiesel for military, mining, industrial and personal transportation applications.

The universities jointly will pursue private and federal funding sources in the U.S. and Australia to develop pilot processing plants, and for design, construction, technology transfer and operation of a cellulosic biofuels program.

Paul Greenfield, vice chancellor of The University of Queensland, said the need for alternative energy sources, such as biofuels, has become an essential part of an environmentally suitable future.

"The development of clean fuels for the future is one of the most urgent challenges facing society due to the need to address climate change and secure fuel supplies," Greenfield said.

From an economic development standpoint, the partnership will bring rich rewards, said John Kelly, Clemson University's vice president for economic development.

"Cle
'/>"/>

Contact: Karl Kelly
karl@clemson.edu
864-993-1981
Clemson University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. NIH awards Clemson bioengineer $1.5 million to improve durability of tissue heart valves
2. National Science Foundation grants Clemson professors award to develop nanoprobes
3. US Senate confirms Clemson University engineering Dean Esin Gulari to National Science Board
4. Clemson researchers advance nano-scale electromechanical sensors
5. Clemson physicist Apparao Rao named Fellow of the American Physical Society
6. Clemson chemists present revolutionary teaching concepts
7. Clemson and collaborators receive $1.1 million to improve durability of concrete infrastructure
8. Clemson research nets $2 million from NSF to mimic natures probes
9. Clemson researchers study energy savings with electric cars and IntelliDrive technology
10. Clemson bioengineer uses nanoparticles to target drugs
11. National Institutes of Health award Clemson $9.3 million for tissue regeneration center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... disabilities who are struggling to regain the use of ... engineers and students from Rochester Institute of Technology. ... the human body, to improve the performance of external ... disabilities, such as strokes or major spinal cord injuries, ...
... know all there is to know about Escherichia coli, ... has more than four thousand genes, and the functions ... Siegele, a biology professor at Texas A&M University whose ... , Harmless E. coli strains are normally found in ...
... Understanding, through its Institute for Arctic Studies, has ... Science Foundation through its Integrative Graduate Education and ... grant supports the development of an interdisciplinary doctoral ... a focus on rapid environmental change. "This grant ...
Cached Biology News:Robotics research: Enhancing the lives of people with disabilities 2GIANT-Coli: A novel method to quicken discovery of gene function 2Dartmouth awarded NSF grant for new polar sciences, engineering grad program 2Dartmouth awarded NSF grant for new polar sciences, engineering grad program 3
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO corn ... company, Syngenta, are in the process of being consolidated in ... is In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... of Kansas. , Management of the Syngenta GMO corn multidistrict ...
(Date:12/24/2014)... 23, 2014 The report provides ... definition, classification, application and industry overview. This report ... cost structure. Production is separated by regions, technology ... materials, equipment, downstream client survey, marketing channels, industry ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... MATK ) announced today that life,sDHA(TM), its ... and heart health, is now available to,consumers in ... Challenge,Dairy Products, Inc. Challenge 15 oz. Spreadable Butter ... Founded in 1911, Challenge Dairy Products, Inc., is ...
... Calif., Feb. 4 CV,Therapeutics, Inc. (Nasdaq: ... the companies have entered into an agreement under,which ... technology to develop a drug eluting stent (DES). ... development milestone payments,royalties and other potential payments on ...
... Outside of North ... America, ... facility in Cartago, Costa Rica has been,recognized with the 2008 Shingo Prize ... Prize outside North America,-- is being honored for its achievements in driving ...
Cached Biology Technology:Challenge Spreadable Butter Now Features Martek's life'sDHA(TM) 2Challenge Spreadable Butter Now Features Martek's life'sDHA(TM) 3CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology 2CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology 3Baxter's Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing 2
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
... off the clot fasted non-Swiss Albino mice of mixed ... N-02: Citrate N-04: Heparin ... Oxalate N-10: EDTA (Na) N-03: ... N-09: K3EDTA N-11: Heparin (K) ...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
Biology Products: